Company intelligence / Profile preview
EditForce
Fukuoka, Fukuoka, Japan
- Ownership
- Private
- Development stage
- Other
01
Overview
EditForce is developing PPR protein–based RNA/DNA editing therapies, with a lead AAV-delivered program EF-210 targeting DMPK for myotonic dystrophy type 1 that has shown promising efficacy in mouse models and is planned to enter clinical trials around 2027 in Japan and the U.S.[2][5]
- Therapeutic areas
- OncologyNeurology
- Modalities
- Gene therapyAAV based gene therapyRNA therapyBiologic
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Kyushu UniversityHiroshima UniversityJapan Innovative TherapeuticsSolasia PharmaMitsubishi Tanabe PharmaNew Energy and Industrial Technology Development Organization (NEDO)Japan Agency for Medical Research and Development (AMED)
Beyond the preview
Go deeper on EditForce.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EditForce.